Rezolute (NASDAQ:RZLT) Releases Earnings Results, Misses Estimates By $0.14 EPS

Posted by Oscar Bower on Sep 21st, 2024

Rezolute (NASDAQ:RZLT – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.14), Zacks reports.

Rezolute Price Performance

Rezolute stock opened at $5.08 on Friday. The stock has a market cap of $203.89 million, a PE ratio of -4.46 and a beta of 1.18. The stock’s fifty day moving average is $4.62 and its two-hundred day moving average is $3.72. Rezolute has a 1-year low of $0.72 and a 1-year high of $6.10.

Wall Street Analysts Forecast Growth

RZLT has been the topic of a number of research analyst reports. Maxim Group boosted their price target on shares of Rezolute from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Tuesday, August 6th. JMP Securities restated a “market outperform” rating and set a $7.00 price target on shares of Rezolute in a research note on Friday. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Rezolute in a research note on Monday, September 9th. Guggenheim started coverage on Rezolute in a research note on Tuesday, August 27th. They set a “buy” rating and a $11.00 target price on the stock. Finally, Craig Hallum initiated coverage on shares of Rezolute in a research note on Tuesday, June 4th. They set a “buy” rating and a $14.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Rezolute currently has a consensus rating of “Buy” and a consensus price target of $11.57.

Check Out Our Latest Analysis on Rezolute

Rezolute Company Profile

(Get Free Report)

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.